INCIPIENT: INtraventricular CARv3-TEAM-E T Cells for PatIENTs With GBM
This study tests a special type of engineered immune cell therapy called CARv3-TEAM-E T cells to find the safest and most effective dose for treating glioblastoma, a fast-growing brain tumor. The goal is to see if these modified immune cells can help patients whose brain tumors have returned after previous treatments.
You might be able to join if you have a confirmed returning glioblastoma with specific genetic features and have already gone through prior treatments like radiation therapy. However, people with tumors in certain brain areas or those who have had specific previous gene therapies cannot take part.
Participants will receive the CARv3-TEAM-E T cell treatment directly into the fluid-filled spaces of the brain, and doctors will carefully monitor your safety and response. You will also need to have certain medical checks, tissue samples taken, and wait specific times after past treatments before starting.
This study is currently recruiting participants and takes place in Boston, Massachusetts, United States.
- 1Tests a new immune cell therapy for returning glioblastoma
- 2Study is currently active and recruiting patients in Boston
- 3Involves specific requirements regarding prior treatments and tumor genetics
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.